Q1 2021 13F Holders as of 31 Mar 2021
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
54,711,345
-
Total 13F shares
-
38,422,385
-
Share change
-
-224,871
-
Total reported value
-
$1,492,282,987
-
Put/Call ratio
-
144%
-
Price per share
-
$38.84
-
Number of holders
-
104
-
Value change
-
-$15,747,693
-
Number of buys
-
54
-
Number of sells
-
38
Institutional Holders of Stoke Therapeutics, Inc. - Common Stock, $0.0001 par value per share (STOK) as of Q1 2021
As of 31 Mar 2021,
Stoke Therapeutics, Inc. - Common Stock, $0.0001 par value per share (STOK) was held by
104 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
38,422,385 shares.
The largest 10 holders included
ATP Life Science Ventures, L.P., RTW INVESTMENTS, LP, FMR LLC, Redmile Group, LLC, VANGUARD GROUP INC, BlackRock Inc., Cormorant Asset Management, LP, GILDER GAGNON HOWE & CO LLC, FEDERATED HERMES, INC., and STATE STREET CORP.
This page lists
104
institutional shareholders reporting positions in this security
for the Q1 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.